A UK study in BMC Medicine reports that extending the prognostic window from six to twelve months changed who received fast-tracked access to end-of-life benefits under the Special Rules for End of Life pathway. The paper analyzes how the rule change in 2022—doubling the statutory threshold—altered eligibility timing and access patterns. While the finding is policy-driven rather than drug development, it is relevant to healthcare operations and patient access because it affects downstream care planning, clinical documentation practices, and the timing of supportive and palliative interventions. The results provide an evidence-backed assessment of how administrative thresholds can reshape access in real-world settings.